Drospirenone (DRSP) is a new progestin with antialdosterone and antiandrogenic activity that has been developed for postmenopausal hormone therapy in combination with 17-beta estradiol (E2). In prior studies, DRSP/E2 has been associated with significant reductions in blood pressure (BP) measured by standard sphygmomanometry in women with essential hypertension. In the present study, the effects of DRSP/E2 on clinic and 24-hour systolic BP (SBP) was evaluated in postmenopausal women with stage 1 systolic hypertension (Ͼ 140 mmHg).
DRSP/E2 has been associated with significant reductions in blood pressure (BP) measured by standard sphygmomanometry in women with essential hypertension. In the present study, the effects of DRSP/E2 on clinic and 24-hour systolic BP (SBP) was evaluated in postmenopausal women with stage 1 systolic hypertension (Ͼ 140 mmHg).
We performed a 12-week multicenter, double-blind, randomized, placebo-controlled study with DRSP 3 mg ϩ 1 mg E2 in 212 postmenopausal women with stage 1 hypertension (BP ϭ 140/90 to 159/99 mmHg). Clinic and ambulatory BP, as well as potassium (K ϩ ) levels, were measured at baseline and following 12 weeks of therapy. Baseline BPs and demographics were similar in the treatment groups.
Clinic and ambulatory SBP were both reduced significantly on DRSP/E2 compared with placebo (Table) . There were no significant changes from baseline in K ϩ levels, nor in the incidence of hyperkalemia in women taking DRSP/E2 compared with those on placebo. This study confirms that the hormonal therapy DRSP/E2 significantly lowers both clinic and ambulatory BP in postmenopausal women with stage 1 systolic hypertension, a therapeutic characteristic that may be associated with cardiovascular risk reduction in this population. -1 (ng/ml) 197 (173-228) 180 (145-196) 195 (175-220) 0.006 TIMP-2 (ng/ml) 140 (105-168) 138 (110-174) 180 (120-220) 0 
